12/16/2020 12:39 PM
Clarín.com
Society
Updated 12/16/2020 12:39 PM
The first doses of the Russian Sputnik V vaccine against the coronavirus
would arrive in Argentina next Wednesday, December 23
, as
high government sources
confirmed to
Clarín
.
Last Thursday, when announcing the signing of the agreement with Russia, President Alberto Fernández had anticipated that before the end of the year 600,000 doses would arrive, with which 300,000 people could be vaccinated.
However, in recent days the voices that questioned that statement have grown.
The problem, in addition to the logistics, is that everything indicates that the Russian vaccine will set foot on Argentine soil
without the endorsement of the regulatory entities
of the United States (FDA) and the European Community (EMA).
That is why officials from the Anmat - the body that must authorize the country - traveled to Russia to evaluate the vaccine and allow its emergency application.
A dose of the vaccine developed in Moscow by the Gamaleya Institute.
Photo: EFE
The contract contemplates that between January and February another 20 million doses will arrive and a preference in favor of Argentina to be able to vaccinate another 5 million people in March.
The official position is that it was important to close this acquisition in case the rest of the vaccines with which they also have contracts delay their arrival.
In this sense, the Minister of Health, Ginés González García, admitted that the possibility of reaching a purchase agreement with Pfizer is still immature.
"In the negotiation we were asked for a law to have some security, to give them that immunity, and later it appeared in the negotiation that it was not enough, that a new law had to be made and that the contract was not signed by me and signed by President.
Strictly speaking, they are unacceptable conditions
and we have asked you to reveal that, "said González García about the vaccine developed by the US laboratory.
The Gamaleya Center, which develops Sputnik V, assured that it achieved an
efficacy against the coronavirus of 91.4% in 22 thousand volunteers
and highlighted the importance of the contract signed with Argentina to receive the drug.
No unexpected adverse events were identified as part of the investigation, a statement said.
And he adds that the health conditions of the participants will be monitored for at least 6 months after receiving the first vaccine.
AFG
Look also
Vaccine against the coronavirus: the plot of why Argentina has not yet managed to close an agreement with Pfizer
Fernán Quirós and the lack of data on the Russian vaccine against coronavirus: "There is only journalistic information"